DeNovo Ventures

Total investments

96

Average round size

21M

Portfolio companies

39

Rounds per year

4.00

Lead investments

14

Follow on index

0.59

Exits

20

Stages of investment
Private EquityEarly Stage VentureLate Stage Venture
Areas of investment
Therapeutic DevicesBiotechnologyHealth CareHealth DiagnosticsManufacturingMedical DeviceMedicalPharmaceuticalTherapeuticsBiopharma

Summary

In 2000 was created DeNovo Ventures, which is appeared as VC. The main office of represented VC is situated in the Saratoga. The venture was found in North America in United States.

The top amount of exits for fund were in 2019. The real fund results show that this VC is 5 percentage points less often commits exit comparing to other companies. Comparing to the other companies, this DeNovo Ventures performs on 11 percentage points less the average number of lead investments. The important activity for fund was in 2007. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in 2-6 deals per year. When the investment is from DeNovo Ventures the average startup value is 100-500 millions dollars.

The fund was created by David M. Mauney, Richard Ferrari. We also calculated 4 valuable employees in our database.

For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the various public portfolio startups of the fund, we may underline EndoGastric Solutions, EBR Systems, TRIA Beauty Besides, a startup needs to be aged 6-10 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Medical, Biopharma. The fund has specific favorite in a number of founders of portfolio startups. If startup sums 3 or 5+ of the founder, the chance for it to be financed is low.

The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the DeNovo Ventures, startups are often financed by Advanced Technology Ventures, Delphi Ventures, Versant Ventures. The meaningful sponsors for the fund in investment in the same round are Versant Ventures, SV Health Investors, Prism Venture Management. In the next rounds fund is usually obtained by SV Health Investors, Johnson & Johnson Development Corporation, Foundation Medical Partners.

Show more

Investments analytics

Analytics

Total investments
96
Lead investments
14
Exits
20
Rounds per year
4.00
Follow on index
0.59
Investments by industry
  • Health Care (76)
  • Medical Device (60)
  • Biotechnology (47)
  • Medical (34)
  • Health Diagnostics (16)
  • Show 19 more
Investments by region
  • United States (95)
Peak activity year
2007

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
19
Avg. valuation at time of investment
7M
Group Appearance index
0.96
Avg. company exit year
11
Avg. multiplicator
0.18

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Milo 08 Jan 2023 Information Technology, Consumer Electronics, Communication Hardware, Audio Early Stage Venture 12M
OncoMed Pharmaceuticals 04 Nov 2008 Biotechnology, Health Care, Pharmaceutical Early Stage Venture 154M United States, California, Redwood City

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.